01|03|07 – Neuropharm Group plc, a speciality pharmaceutical group focused on the development of products for the treatment of disorders of the central nervous system (CNS), is pleased to announce that it intends to join the AIM market by way of a Placing by Investec Investment Banking to raise £20.0 million (gross). Neuropharm has today published its Admission Document and it is expected that dealings in the Company’s Ordinary Shares will commence next week under the ticker symbol NPH.
